Monte Rosa Therapeutics, Inc. (GLUE) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Monte Rosa Therapeutics reported revenue of $123.7M, up 63.5% from $75.6M the year before. Net income was -$38.6M (a -31.2% net margin), or -$0.46 per diluted share. Operating margin was -43.8%. Operating activities generated -$22.8M of cash, leaving -$27.5M of free cash flow. At fiscal year end, Monte Rosa Therapeutics held $448.7M in total assets against $215.6M in total liabilities, including $129.9M of cash and equivalents.
Open the full interactive Monte Rosa Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Monte Rosa Therapeutics Key Stats
| Share Price | $9.89 |
|---|---|
| Market Cap | $1.00B |
| Revenue YoY Growth | +63.5% |
| 52-Week Range | $9.35 – $25.31 |
| Shares Outstanding | 101.5 million (basic, 2026 Q2) |
Monte Rosa Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $75.6M | $123.7M |
| Operating Income | -$72.9M | -$112.4M | -$143.3M | -$81.1M | -$54.2M |
| Pre-Tax Income | -$74.0M | -$108.5M | -$135.0M | -$70.1M | -$39.7M |
| Income Tax | — | — | $338,000 | $2.6M | -$1.1M |
| Net Income | -$74.0M | -$108.5M | -$135.4M | -$72.7M | -$38.6M |
| Diluted EPS | -$2.96 | -$2.30 | -$2.63 | -$0.98 | -$0.46 |
Monte Rosa Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $12.8M | $2.8M | $4.2M | $9.0M |
| Net Income | -$27.1M | -$46.1M | -$44.5M | -$43.4M |
| Diluted EPS | -$0.33 | -$0.56 | -$0.45 | -$0.43 |
Monte Rosa Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $346.1M | $54.9M | $128.1M | $224.3M | $129.9M |
| Current Assets | $348.7M | $275.9M | $236.2M | $377.4M | $393.2M |
| Total Assets | $366.3M | $342.4M | $303.8M | $438.7M | $448.7M |
| Current Liabilities | $16.6M | $25.6M | $46.6M | $156.9M | $64.2M |
| Total Liabilities | $18.8M | $71.0M | $124.5M | $215.8M | $215.6M |
| Shareholders' Equity | $347.5M | $271.4M | $179.2M | $222.9M | $233.1M |
Monte Rosa Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$59.4M | -$92.5M | -$43.8M | $42.0M | -$22.8M |
| Cash From Investing | -$9.7M | -$219.2M | $88.8M | -$44.5M | -$101.8M |
| Cash From Financing | $377.6M | $20.5M | $27.5M | $98.9M | $30.4M |
| Free Cash Flow | -$69.1M | -$105.4M | -$62.8M | $38.0M | -$27.5M |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
Figures from Monte Rosa Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Monte Rosa Therapeutics financials page for every line item.
Monte Rosa Therapeutics Company Profile
| Ticker | GLUE |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Boston, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001826457 |
Frequently Asked Questions
What was Monte Rosa Therapeutics' revenue in fiscal 2025?
Monte Rosa Therapeutics (GLUE) reported revenue of $123.7M for fiscal 2025.
What is Monte Rosa Therapeutics' annual revenue history?
Monte Rosa Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $75.6M; 2025: $123.7M.
What was Monte Rosa Therapeutics' net income in fiscal 2025?
Monte Rosa Therapeutics reported net income of -$38.6M for fiscal 2025.
What was Monte Rosa Therapeutics' earnings per share (EPS) in fiscal 2025?
Monte Rosa Therapeutics' diluted EPS was -$0.46 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Monte Rosa Therapeutics generate in fiscal 2025?
Monte Rosa Therapeutics generated -$27.5M of free cash flow in fiscal 2025.
What was Monte Rosa Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Monte Rosa Therapeutics reported revenue of $9.0M.
How many shares of Monte Rosa Therapeutics are outstanding?
Monte Rosa Therapeutics reported a weighted average of 101.5 million basic shares outstanding in 2026 Q2.
What is Monte Rosa Therapeutics' market cap?
Based on its latest closing price, Monte Rosa Therapeutics (GLUE) has a market capitalization of about $1.00B.
When does Monte Rosa Therapeutics' fiscal year end?
Monte Rosa Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Monte Rosa Therapeutics headquartered?
Monte Rosa Therapeutics lists its business address in Boston, Massachusetts in its SEC filings.
Monte Rosa Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →